Abstract
1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49%, at 5 years, 33% and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5=year survivors after megatherapy with BMT for stage 4 disease do have an 80% chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15% survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17% toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event=free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.
| Original language | English |
|---|---|
| Pages (from-to) | 2130-2135 |
| Number of pages | 6 |
| Journal | European Journal of Cancer |
| Volume | 33 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Oct 1997 |
Fingerprint
Keywords
- EBMT
- Myeloablative therapy
- Neuroblastoma
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma : 17 years of european experience and conclusions. / Philip, T.; Ladenstein, R.; Lasset, C.; Hartmann, O.; Zucker, J. M.; Pinkerton, R.; Pearson, A. D J; Klingebiel, T.; Garaventa, A.; Kremens, B.; Bernard, J. L.; Rosti, G.; Chauvin, F.
In: European Journal of Cancer, Vol. 33, No. 12, 10.1997, p. 2130-2135.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma
T2 - 17 years of european experience and conclusions
AU - Philip, T.
AU - Ladenstein, R.
AU - Lasset, C.
AU - Hartmann, O.
AU - Zucker, J. M.
AU - Pinkerton, R.
AU - Pearson, A. D J
AU - Klingebiel, T.
AU - Garaventa, A.
AU - Kremens, B.
AU - Bernard, J. L.
AU - Rosti, G.
AU - Chauvin, F.
PY - 1997/10
Y1 - 1997/10
N2 - 1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49%, at 5 years, 33% and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5=year survivors after megatherapy with BMT for stage 4 disease do have an 80% chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15% survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17% toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event=free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.
AB - 1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49%, at 5 years, 33% and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5=year survivors after megatherapy with BMT for stage 4 disease do have an 80% chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15% survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17% toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event=free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.
KW - EBMT
KW - Myeloablative therapy
KW - Neuroblastoma
UR - http://www.scopus.com/inward/record.url?scp=0031431549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031431549&partnerID=8YFLogxK
U2 - 10.1016/S0959-8049(97)00324-9
DO - 10.1016/S0959-8049(97)00324-9
M3 - Article
C2 - 9516868
AN - SCOPUS:0031431549
VL - 33
SP - 2130
EP - 2135
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 12
ER -